NPI: 1073890463 · NEW ORLEANS, LA 70115 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 11/14/2011
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 11/14/2011 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,301 | $37K |
| 2019 | 4,410 | $14K |
| 2020 | 2,360 | $621.30 |
| 2021 | 1,258 | $8K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 386 | 52 | $43K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 9,475 | 698 | $16K |
| A4657 | Syringe, with or without needle, each | 1,687 | 645 | $2K |
| 83540 | 157 | 131 | $0.00 | |
| 83970 | 622 | 480 | $0.00 | |
| 85048 | 370 | 326 | $0.00 | |
| 85041 | 370 | 326 | $0.00 | |
| 82108 | 103 | 70 | $0.00 | |
| J1270 | Injection, doxercalciferol, 1 mcg | 708 | 64 | $0.00 |
| 82728 | 200 | 159 | $0.00 | |
| 83550 | 159 | 132 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 15 | 12 | $0.00 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 56 | 29 | $0.00 |
| 86706 | 21 | 14 | $0.00 |